Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;80(1-2):295–300. doi: 10.1038/sj.bjc.6690354

Mutation testing in melanoma families: INK4A, CDK4 and INK4D

J A Newton Bishop 2, M Harland 1, D C Bennett 3, V Bataille 4, A M Goldstein 5, M A Tucker 5, B A J Ponder 6, J Cuzick 7, P Selby 2, D T Bishop 1
PMCID: PMC2363010  PMID: 10390011

Abstract

The INK4A gene which codes for the cyclin-dependent kinase (CDK) inhibitor INK4A or p16 underlies susceptibility to melanoma in some families. Germline mutations in the gene that codes for the target protein of p16, CDK4, underlie susceptibility in very rare families. We report mutation screening of the INK4A and CDK4 genes in 42 UK families. A total of nine families were identified with INK4A mutations and none with CDK4 exon 2 mutations. These mutations were in 8/22 (35%) families with three or more cases of melanoma and 1/20 (5%) families with only two cases. In one of these nine families a novel single base pair substitution was identified, Gly67Arg. In an attempt to identify another melanoma susceptibility gene, a member of the INK4 family, the p19 INK4D gene has been studied. The p19 gene was sequenced in DNA from the 42 UK families and six additional US families. No mutations were identified. © 1999 Cancer Research Campaign

Keywords: INK4A, INK4D, familial melanoma

Full Text

The Full Text of this article is available as a PDF (92.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bale S. J., Dracopoli N. C., Tucker M. A., Clark W. H., Jr, Fraser M. C., Stanger B. Z., Green P., Donis-Keller H., Housman D. E., Greene M. H. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med. 1989 May 25;320(21):1367–1372. doi: 10.1056/NEJM198905253202102. [DOI] [PubMed] [Google Scholar]
  2. Bergman W., Watson P., de Jong J., Lynch H. T., Fusaro R. M. Systemic cancer and the FAMMM syndrome. Br J Cancer. 1990 Jun;61(6):932–936. doi: 10.1038/bjc.1990.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cannon-Albright L. A., Goldgar D. E., Meyer L. J., Lewis C. M., Anderson D. E., Fountain J. W., Hegi M. E., Wiseman R. W., Petty E. M., Bale A. E. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science. 1992 Nov 13;258(5085):1148–1152. doi: 10.1126/science.1439824. [DOI] [PubMed] [Google Scholar]
  4. Clark W. H., Jr, Reimer R. R., Greene M., Ainsworth A. M., Mastrangelo M. J. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol. 1978 May;114(5):732–738. [PubMed] [Google Scholar]
  5. Coleman K. G., Wautlet B. S., Morrissey D., Mulheron J., Sedman S. A., Brinkley P., Price S., Webster K. R. Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J Biol Chem. 1997 Jul 25;272(30):18869–18874. doi: 10.1074/jbc.272.30.18869. [DOI] [PubMed] [Google Scholar]
  6. Dracopoli N. C., Fountain J. W. CDKN2 mutations in melanoma. Cancer Surv. 1996;26:115–132. [PubMed] [Google Scholar]
  7. FitzGerald M. G., Harkin D. P., Silva-Arrieta S., MacDonald D. J., Lucchina L. C., Unsal H., O'Neill E., Koh J., Finkelstein D. M., Isselbacher K. J. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8541–8545. doi: 10.1073/pnas.93.16.8541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gemma A., Takenoshita S., Hagiwara K., Okamoto A., Spillare E. A., McMemamin M. G., Hussain S. P., Forrester K., Zariwala M., Xiong Y. Molecular analysis of the cyclin-dependent kinase inhibitor genes p15INK4b/MTS2, p16INK4/MTS1, p18 and p19 in human cancer cell lines. Int J Cancer. 1996 Nov 27;68(5):605–611. doi: 10.1002/(SICI)1097-0215(19961127)68:5<605::AID-IJC9>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  9. Goldstein A. M., Dracopoli N. C., Engelstein M., Fraser M. C., Clark W. H., Jr, Tucker M. A. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet. 1994 Mar;54(3):489–496. [PMC free article] [PubMed] [Google Scholar]
  10. Goldstein A. M., Dracopoli N. C., Ho E. C., Fraser M. C., Kearns K. S., Bale S. J., McBride O. W., Clark W. H., Jr, Tucker M. A. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet. 1993 Mar;52(3):537–550. [PMC free article] [PubMed] [Google Scholar]
  11. Goldstein A. M., Tucker M. A. Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst. 1997 May 21;89(10):676–678. doi: 10.1093/jnci/89.10.676. [DOI] [PubMed] [Google Scholar]
  12. Gruis N. A., Bergman W., Frants R. R. Locus for susceptibility to melanoma on chromosome lp. N Engl J Med. 1990 Mar 22;322(12):853–854. doi: 10.1056/nejm199003223221217. [DOI] [PubMed] [Google Scholar]
  13. Guan K. L., Jenkins C. W., Li Y., O'Keefe C. L., Noh S., Wu X., Zariwala M., Matera A. G., Xiong Y. Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4. Mol Biol Cell. 1996 Jan;7(1):57–70. doi: 10.1091/mbc.7.1.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Harland M., Meloni R., Gruis N., Pinney E., Brookes S., Spurr N. K., Frischauf A. M., Bataille V., Peters G., Cuzick J. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet. 1997 Nov;6(12):2061–2067. doi: 10.1093/hmg/6.12.2061. [DOI] [PubMed] [Google Scholar]
  15. Hirama T., Koeffler H. P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood. 1995 Aug 1;86(3):841–854. [PubMed] [Google Scholar]
  16. Hussussian C. J., Struewing J. P., Goldstein A. M., Higgins P. A., Ally D. S., Sheahan M. D., Clark W. H., Jr, Tucker M. A., Dracopoli N. C. Germline p16 mutations in familial melanoma. Nat Genet. 1994 Sep;8(1):15–21. doi: 10.1038/ng0994-15. [DOI] [PubMed] [Google Scholar]
  17. Kamb A., Shattuck-Eidens D., Eeles R., Liu Q., Gruis N. A., Ding W., Hussey C., Tran T., Miki Y., Weaver-Feldhaus J. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet. 1994 Sep;8(1):23–26. doi: 10.1038/ng0994-22. [DOI] [PubMed] [Google Scholar]
  18. Liu L., Goldstein A. M., Tucker M. A., Brill H., Gruis N. A., Hogg D., Lassam N. J. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF. Genes Chromosomes Cancer. 1997 May;19(1):52–54. [PubMed] [Google Scholar]
  19. Lynch H. T., Fusaro R. M. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas. 1991 Mar;6(2):127–131. doi: 10.1097/00006676-199103000-00001. [DOI] [PubMed] [Google Scholar]
  20. MacGeoch C., Bishop J. A., Bataille V., Bishop D. T., Frischauf A. M., Meloni R., Cuzick J., Pinney E., Spurr N. K. Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet. 1994 Dec;3(12):2195–2200. doi: 10.1093/hmg/3.12.2195. [DOI] [PubMed] [Google Scholar]
  21. Miller C. W., Yeon C., Aslo A., Mendoza S., Aytac U., Koeffler H. P. The p19INK4D cyclin dependent kinase inhibitor gene is altered in osteosarcoma. Oncogene. 1997 Jul 10;15(2):231–235. doi: 10.1038/sj.onc.1201185. [DOI] [PubMed] [Google Scholar]
  22. Nancarrow D. J., Mann G. J., Holland E. A., Walker G. J., Beaton S. C., Walters M. K., Luxford C., Palmer J. M., Donald J. A., Weber J. L. Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet. 1993 Oct;53(4):936–942. [PMC free article] [PubMed] [Google Scholar]
  23. Nancarrow D. J., Palmer J. M., Walters M. K., Kerr B. M., Hafner G. J., Garske L., McLeod G. R., Hayward N. K. Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees. Genomics. 1992 Jan;12(1):18–25. doi: 10.1016/0888-7543(92)90401-d. [DOI] [PubMed] [Google Scholar]
  24. Nelson M. A., Thompson F. H., Emerson J., Aickin M., Adair L., Trent J. M., Leong S. P., Taetle R. Clinical implications of cytogenetic abnormalities in melanoma. Surg Clin North Am. 1996 Dec;76(6):1257–1271. doi: 10.1016/s0039-6109(05)70513-2. [DOI] [PubMed] [Google Scholar]
  25. Newton J. A. Genetics of melanoma. Br Med Bull. 1994 Jul;50(3):677–687. doi: 10.1093/oxfordjournals.bmb.a072916. [DOI] [PubMed] [Google Scholar]
  26. Parmiter A. H., Balaban G., Herlyn M., Clark W. H., Jr, Nowell P. C. A t(1;19) chromosome translocation in three cases of human malignant melanoma. Cancer Res. 1986 Mar;46(3):1526–1529. [PubMed] [Google Scholar]
  27. Platz A., Hansson J., Månsson-Brahme E., Lagerlof B., Linder S., Lundqvist E., Sevigny P., Inganäs M., Ringborg U. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst. 1997 May 21;89(10):697–702. doi: 10.1093/jnci/89.10.697. [DOI] [PubMed] [Google Scholar]
  28. Ranade K., Hussussian C. J., Sikorski R. S., Varmus H. E., Goldstein A. M., Tucker M. A., Serrano M., Hannon G. J., Beach D., Dracopoli N. C. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet. 1995 May;10(1):114–116. doi: 10.1038/ng0595-114. [DOI] [PubMed] [Google Scholar]
  29. Sherr C. J. Cancer cell cycles. Science. 1996 Dec 6;274(5293):1672–1677. doi: 10.1126/science.274.5293.1672. [DOI] [PubMed] [Google Scholar]
  30. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995 May 15;9(10):1149–1163. doi: 10.1101/gad.9.10.1149. [DOI] [PubMed] [Google Scholar]
  31. Shiohara M., Spirin K., Said J. W., Gombart A. F., Nakamaki T., Takeuchi S., Hatta Y., Morosetti R., Tasaka T., Seriu T. Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies. Leukemia. 1996 Dec;10(12):1897–1900. [PubMed] [Google Scholar]
  32. Walker G. J., Hussussian C. J., Flores J. F., Glendening J. M., Haluska F. G., Dracopoli N. C., Hayward N. K., Fountain J. W. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet. 1995 Oct;4(10):1845–1852. doi: 10.1093/hmg/4.10.1845. [DOI] [PubMed] [Google Scholar]
  33. Walker G. J., Nancarrow D. J., Walters M. K., Palmer J. M., Weber J. L., Hayward N. K. Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer. 1994 Dec 15;59(6):771–775. doi: 10.1002/ijc.2910590611. [DOI] [PubMed] [Google Scholar]
  34. Yang R., Serrano M., Slater J., Leung E., Koeffler H. P. Analysis of p16INK4a and its interaction with CDK4. Biochem Biophys Res Commun. 1996 Jan 5;218(1):254–259. doi: 10.1006/bbrc.1996.0045. [DOI] [PubMed] [Google Scholar]
  35. Zindy F., Quelle D. E., Roussel M. F., Sherr C. J. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene. 1997 Jul 10;15(2):203–211. doi: 10.1038/sj.onc.1201178. [DOI] [PubMed] [Google Scholar]
  36. Zuo L., Weger J., Yang Q., Goldstein A. M., Tucker M. A., Walker G. J., Hayward N., Dracopoli N. C. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996 Jan;12(1):97–99. doi: 10.1038/ng0196-97. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES